TB skin test recombinant proteins as vaccine candidates

I. V. Krasilnikov; Красильников И. В.; T. I. Vinogradova; Виноградова Т. И.; M. Djonovic; Джонович М.; N. V. Zabolotnykh; Заболотных Н. В.; S. A. Arakelov; Аракелов С. А.; M. Z. Dogonadze; Догонадзе М. З.; V. G. Lunin; Лунин В. Г.

doi:10.23868/202209007

TB skin test recombinant proteins as vaccine candidates

Authors: Krasilnikov I.V.¹^,2^,3, Vinogradova T.I.⁴, Djonovic M.²^,5, Zabolotnykh N.V.⁴, Arakelov S.A.¹, Dogonadze M.Z.⁴, Lunin V.G.⁶
Affiliations:
1. Saint-Petersburg Institute of Vaccines and Serums of the FMBA of Russia
2. “The Human Stem Cells Institute” PJSC
3. “Biotechnology Developments” LLC
4. Saint-Peterburg Petersburg Research Institute of Phthisiopulmonology
5. “Betuvax” LLC
6. N.F. Gamaleya National Research Center for Epidemiology and Microbiology
Issue: Vol 17, No 2 (2022)
Pages: 47-55
Section: Original Study Articles
URL: https://journal-vniispk.ru/2313-1829/article/view/143493
DOI: https://doi.org/10.23868/202209007
ID: 143493

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Incomplete protection of BCG vaccines, high variability of tuberculosis strains, together with the growing antibiotic resistance of mycobacterium tuberculosis, actualize the need to develop new anti-tuberculosis vaccines. Several novel experimental candidate vaccines based on recombinant proteins, such as those based on the M. tuberculosis ESAT-6 and CFP-10 antigens, are currently being studied in clinical trials. The genome region coding for ESAT-6 and CFP-10 antigens is deleted in BCG strains, so the BCG-immunized individuals cannot develop an immune response against the recombinant ESAT-6/CFP-10 antigen. Therefore, a positive immune reaction to these antigens in TB tests indicates the tested individual has earlier been exposed to M. tuberculosis. The ESAT-6/CFP-10 fusion recombinant antigen was, thus, selected as an immunogen to be evaluated on its potential to induce protective immunity against tuberculosis in a mice model when combined with a birch bark betulin-based vaccine adjuvant. The effect of use was assessed based on the results of histological evaluation of the infected lung tissue in mice and the Mtb lung content. The results herein reported eventually demonstrated that the use of corpuscular adjuvant-based (betulin) ESAT-6/CFP-10 vaccine preparation can induce the immune response commensurate to that of when immunized with the BCG vaccine.

Keywords

recombinant protein, corpuscular adjuvant, tuberculosis vaccine, Mycobacterium tuberculosis

Full Text

##article.viewOnOriginalSite##

References

Shenoi S., Friedland G. Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu. Rev. Med. 2009; 60: 307–20.
Bansal R., Sharma D., Singh R. Tuberculosis and its treatment: an overview. Mini Rev. Med. Chem. 2018; 18(1): 58–71.
Dockrell H.M., Smith S.G. What Have We Learnt about BCG Vaccination in the Last 20 Years? Front. Immunol. 2017; 8: 1134.
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac, https://clinicaltrials.gov/ct2/show/NCT04975737.
Старшинова А.А., Довгалюк И.Ф., Яблонский П.К. Иммунодиагностика туберкулеза: десятилетний опыт применения иммунологических тестов в России. Туберкулез и болезни легких 2019; 97(5): 58–65 [Starshinova A.A., Dovgalyuk I.F., Yablonsky P.K. Immunodiagnostics of tuberculosis: a decade of experience in the use of immunological tests in Russia. Tuberculosis and Lung Diseases 2019; 97(5): 58–65].
Porsa E., Cheng L., Seale M.M. et al. Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin. Vaccine Immunol. 2006; 13(1): 53–8.
Hemmati M., Seghatoleslam A., Rasti M. et al. Expression and purification of recombinant Mycobacterium tuberculosis (TB) antigens, ESAT-6, CFP-10 and ESAT-6/CFP-10 and their diagnosis potential for detection of TB patients. Iran. Red Crescent Med. J. 2011; 13(8): 556.
Brock I., Munk M.E., Kok-Jensen A. et al. Performance of whole blood IFN-γ test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int. J. Tuberc. Lung Dis. 2001; 5(5): 462–7.
Ravn P., Munk M.E., Andersen A.B. et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin. Vaccine Immunol. 2005; 12(4): 491–6.
Слогоцкая Л.В., Иванова Д.А., Кочетков Я.А. и соавт. Сравнительные результаты кожного теста с препаратом, содержащим рекомбинантный белок CFP-10-ESAT-6, и лабораторного теста QuantiFERON-GIT. Туберкулез и болезни легких 2012; 10: 27–32 [Slogotskaya L.V., Ivanova D.A., Kochetkov Y.A. et al. Comparative results of a skin test with a preparation containing the recombinant CFP-10-ESAT-6 protein and a QuantiFERON-GIT laboratory test. Tuberculosis and Lung Diseases 2012; 10: 27–32].
Кисличкин Н.Н., Фурс С.М., Красильников И.В. и соавт. Диагностика туберкулеза. Туберкулин или диаскинтест — что выбрать? Эпидемиология и инфекционные болезни. Актуальные вопросы 2014; 5: 50–5 [Kislichkin N.N., Furs S.M., Krasilnikov I.V. et al. Diagnosis of tuberculosis. Tuberculin or diaskintest — what to choose? Epidemiology and infectious diseases. Current Issues 2014; 5: 50–5].
Кисличкин Н.Н., Ленхерр-Ильина Т.В., Красильников И.В. Диагностика туберкулеза. Туберкулин и группа препаратов на основе белков ESAT-6/CFP-10. Инфекционные болезни 2016; 14(1): 48–54 [Kislichkin N.N., Lenherr-Ilyina T.V., Krasilnikov I.V. Diagnosis of tuberculosis. Tuberculin and a group of drugs based on ESAT-6/CFP-10 proteins. Infectious Diseases 2016; 14(1): 48–54].
Krasilnikov I.V., Kudriavtsev A.V., Vakhrusheva A.V. et al. Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2. Vaccines 2022; 10(1): 69.
Tkachuk A.P., Gushchin V.A., Potapov V.D. et al. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One 2017; 12(4): e0176784.
Александрова А.Е., Ариэль Б.М. Оценка тяжести туберкулезного процесса в легких мышей. Проблемы Туберкулеза 1993; 3: 52–3 [Aleksandrova A.E., Ariel B.M. Evaluation of the severity of the tuberculous process in the lungs of mice. Problems of Tuberculosis 1993; 3: 52–3].
Pitt J.M, Blankley S., McShane H. et al. Vaccination against tuberculosis: how can we better BCG. Microb. Pathog. 2013; 58: 2–16.